Longitudinal changes in neurodevelopmental outcomes between 18 and 36 months in children with prenatal triptan exposure: findings from the Norwegian Mother and Child Cohort Study.
This study sought to determine whether changes in neurodevelopmental outcomes between 18 and 36 months of age were associated with prenatal exposure to triptan medications, a class of 5-HT receptor agonists used in the treatment of migraine.



Using data from the Norwegian Mother and Child Cohort Study, a prospective birth cohort that includes nearly 40% of all pregnancies in Norway from 1999 to 2008, we identified 50 469 mother-child dyads who met inclusion criteria and were present for at least one follow-up assessment at 18 or 36 months postpartum. Neurodevelopment was assessed using the Child Behaviour Checklist, the Emotionality, Activity, and Shyness Questionnaire, and the Ages and Stages Questionnaire. We used generalised estimating equations to evaluate change from 18 to 36 months for children prenatally exposed to triptans, relative to contrast groups, and used marginal structural models with inverse probability of treatment and censoring weights to address time-varying exposure and confounding as well as loss to follow-up.



Among eligible participants (n=50 469), 1.0% used a triptan during pregnancy, 2.0% used triptans prior to pregnancy only, 8.0% reported migraine without triptan use and 89.0% had no history of migraine. Children with prenatal triptan exposure had greater increases in emotionality (r-RR 2.18, 95% CI 1.03 to 4.53) and activity problems (r-RR 1.70, 95% CI 1.02 to 2.8) compared to children born to mothers who discontinued triptan use prior to pregnancy.



Prenatal triptan exposure was associated with changes over time in externalising-type behaviours such as emotionality and activity, but not with internalising-type behaviours.
The University of Oslo School of Pharmacy, Oslo, Norway The University of Massachusetts Medical School, Worcester, Massachusetts, USA PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo, Oslo, Norway.
Mollie E
ME
Wood
The University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Jean A
JA
Frazier
PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo, Oslo, Norway The University of Oslo School of Pharmacy and the Norwegian Institute of Public Health, Oslo, Norway.
Hedvig M E
HM
Nordeng
The University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Kate L
KL
Lapane
D000328:Adult; D002652:Child Behavior / Q000187:drug effects*; D002657:Child Development / Q000187:drug effects; D002675:Child, Preschool; D004644:Emotions / Q000187:drug effects; D005260:Female; D006801:Humans; D007223:Infant; D016015:Logistic Models; D008297:Male; D008881:Migraine Disorders / Q000188:drug therapy*; D009664:Norway; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects / Q000139:chemically induced / Q000523:psychology*; D011446:Prospective Studies; D011795:Surveys and Questionnaires; D014363:Tryptamines / Q000009:adverse effects*
D014363:Tryptamines
EPIDEMIOLOGY; MENTAL HEALTH; medication use in pregnancy